Cian Healthcare Board to Consider H1 Results on November 13, 2026

Cian Healthcare Limited will consider unaudited standalone and consolidated financial results for the half-year ended September 30, 2026, at its board meeting on November 13, 2026. The disclosure follows FY2026 revenue of ₹29.47 crore, down 4.5% year-on-year, while the annual net loss narrowed to ₹23.29 crore.

When will Cian Healthcare announce its September 2026 results?

Cian Healthcare is scheduled to consider and approve its September 2026 half-year results on Friday, November 13, 2026. The company informed BSE that its board meeting, referenced as CIAN/BM/2026-27/03, will take up both standalone and consolidated financial statements for the period ended September 30, 2026.

The results are described as unaudited in the company update. They will provide the next reported financial snapshot after the audited standalone and consolidated results for the half-year and financial year ended March 31, 2026, were approved by the board on May 30, 2026.

Cian Healthcare has also stated that its trading window for designated persons will remain closed until 48 hours after the financial results are declared. Such restrictions are used to limit trading by persons covered by insider-trading rules while unpublished price-sensitive information is being considered and released.

What has Cian Healthcare disclosed about the board meeting?

Cian Healthcare has disclosed that the November 13 meeting will consider the financial results for the half-year ended September 30, 2026. The intimation does not provide the new period's revenue, profit or loss figures before the board's consideration and approval.

The meeting follows a series of board actions during 2026. On January 9, the company held a meeting concerning reduction of capital and a preferential issue. Another meeting on January 23 concerned reduction of capital. On January 14, the board considered half-yearly results, while the May 30 meeting considered audited results for the year ended March 31, 2026.

Earlier, the company's unaudited consolidated financial results for the half-year ended September 30, 2025 were approved at a January 14, 2026 board meeting held through video conferencing. The September 2026 results therefore represent the next comparable half-year disclosure in the reported sequence.

How did Cian Healthcare perform in FY2026 and the prior half-year?

Cian Healthcare reported FY2026 revenue of ₹29.47 crore, a decline of 4.5% from FY2025, and a net loss of ₹23.29 crore, which was 10% lower than the preceding year's loss. Full-year loss per share improved to ₹9.32 from ₹10.39 in FY2025.

The company also reported FY2026 sales of ₹28.29 crore, compared with ₹30.79 crore a year earlier. Sales and revenue are presented as separate measures in the supplied disclosures, so they should not be treated as interchangeable without further company explanation.

For the half-year ended September 30, 2025, Cian Healthcare reported sales of ₹11.32 crore, compared with ₹18.90 crore in the corresponding prior-year period. Revenue for that half-year was ₹11.95 crore versus ₹18.97 crore, while net loss narrowed to ₹5.32 crore from ₹18.25 crore.

Basic and diluted loss per share from continuing operations for that period stood at ₹2.13, improving from a loss of ₹7.30 per share a year earlier. The upcoming disclosure will allow investors to compare the September 2026 half-year numbers with these reported figures.

Why do the September results matter for investors and operations?

The September results matter because they will show whether the FY2026 reduction in losses was sustained into the first half of the next reporting cycle. Revenue, sales, net loss and per-share performance will be key reported measures because the company's latest full-year figures showed lower revenue alongside a narrower loss.

The results may also offer context on Cian Healthcare's operating channels. The company reported FY2025 channel sales of ₹34.25 crore, of which third-party sales accounted for ₹24.64 crore, or 72%. Direct exports contributed ₹4.53 crore, merchant exports ₹2.48 crore, government business ₹1.67 crore and other channels ₹0.93 crore.

These channel figures show that third-party sales formed the largest reported part of FY2025 channel sales. The November board-meeting intimation, however, does not state whether the sales-channel mix changed during the half-year ended September 30, 2026.

What is the relevant background to Cian Healthcare's recent disclosures?

Cian Healthcare's recent disclosures include financial reporting, capital-related board matters and actions by its Resolution Plan Implementation Committee. On February 1, 2026, the committee approved audited consolidated financial results for the half-year and year ended March 31, 2025.

The company subsequently disclosed that its board approved audited financial results, an audit report and a statement on the impact of audit qualification for the half-year and year ended March 31, 2026. The supplied material does not specify the details of the audit qualification impact, and the upcoming board-meeting notice does not address it.

For investors, the immediate focus remains the financial results to be considered on November 13. The company has not provided preliminary September 2026 figures in the meeting notice, so conclusions on current-period performance would require the formal results release.

Conclusion

Cian Healthcare will place its unaudited standalone and consolidated financial results for the half-year ended September 30, 2026 before its board on November 13. The announcement comes after FY2026 revenue declined to ₹29.47 crore and the annual net loss narrowed to ₹23.29 crore, making the new disclosure relevant for assessing the direction of reported sales and losses.

Investors should watch for the board-approved revenue, sales, net loss and loss-per-share figures, along with any disclosures on operations, audit matters or capital actions. The trading window will reopen 48 hours after the results are declared, as stated by the company.